Figopitant | 502422-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Figopitant
• 英文别名: (2S)-N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-[4-(cyclopropylmethyl)piperazin-1-yl]-N-methyl-2-phenylacetamide
• CAS: 502422-74-4
• 化学式: C₂₇H₃₁F₆N₃O
• 分子量: 527.5
• InChiKey: HUTHJVYJUPXHDF-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• NK1-antagonist combination and method for treating synucleinopathies
  申请人：CHASE THERAPEUTICS CORPORATION

  公开号：US11160809B2

  公开（公告）日：2021-11-02

  The present invention describes the use of a NK1-antagonist, in combination with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose to act without the typical adverse effects caused by pramipexole dihydrochloride monohydrate when administered alone.

  本发明描述了一种NK1-拮抗剂与6-丙基氨基-4,5,6,7-四氢-1,3-苯并噻唑-2-胺联合使用，通过使治疗有效的6-丙基氨基-4、 5,6,7-四氢-1,3-苯并噻唑-2-胺的每日剂量，而不会产生普拉克索二盐酸盐一水合物单独给药时引起的典型不良反应。
• Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
  申请人：DAS-MG, Inc.

  公开号：US11389420B2

  公开（公告）日：2022-07-19

  The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.

  本发明描述了一种 NK1-拮抗剂与新斯的明的恒定组合使用，通过提供治疗有效的溴化新斯的明或硫酸甲酯每日剂量而无剂量限制性胃肠道不良反应，从而促进对患有重症肌无力的患者的治疗。
• PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND A NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS
  申请人：DAS-MG, Inc.

  公开号：US20200155495A1

  公开（公告）日：2020-05-21

  The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.
• PHARMACEUTICAL COMPOSITIONS AND METHOD UTILIZING PYRIDOSTIGMINE AND A NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS
  申请人：DAS-MG, Inc.

  公开号：US20200155530A1

  公开（公告）日：2020-05-21

  The present invention describes the use of a NK1-antagonist, in constant combination with pyridostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective pyridostigmine bromide daily dose without the dose-limiting gastro-intestinal adverse effects.
• COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
  申请人：CHASE THERAPEUTICS CORPORATION

  公开号：US20210338652A1

  公开（公告）日：2021-11-04

  The present invention provides a pharmaceutical combination comprising an inhibitor of dopamine agonist adverse effects and a dopamine agonist, for treating Parkinson's disease and Parkinson's disease-related disorders.